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Parenteral pentavalent antimonials remain the standard therapy for
cutaneous leishmaniasis. More effective and patient-compliant topical
treatments are an important alternative treatment for the localized,
self-limiting forms of this disease. Two paromomycin ointments are
commercially available but their use is limited by either toxicity or lack
of efficacy. Other topical formulations have been in clinical trials, but
many results have been equivocal and no major breakthroughs have
been achieved. The focus of this review is on recent developments in
the field of topical treatment for cutaneous leishmaniasis and rational
approaches to enhance topical drug absorption.
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Introduction
Leishmaniasis is a widespread disease with both visceral and
cutaneous manifestations. Cutaneous leishmaniasis (CL) is the
most common form of this disease. It has an annual incidence
of 1 to 1.5 million cases and is endemic in 88 countries; 90% of
cases are reported in just six countries, Afghanistan, Brazil, Iran,
Peru, Saudi Arabia and Syria [1]. These numbers are probably
an underestimate as leishmaniasis is a notifiable disease in only
40 of the 88 countries. There is evidence to suggest that the
worldwide incidence is increasing, probably due to improved
reporting, population migration, seasonal/climatic changes,
HIV co-infection and agro-industrial development in endemic
areas [2].
The clinical manifestations of CL result from the interaction of
factors including, parasite species, site of inoculation and host
immune status. Although the disease is normally localized to
the site of infection within dermal macrophages, metastasis to
lymphatic, mucosal and bone marrow sites can occur [3]. After
parasites are inoculated into the mammalian host by the
sandfly vector, they are engulfed by macrophages where the
intracellular amastigotes survive and divide within the
parasitophorous vacuole. The manifestations of CL encompass
a wide spectrum of severities and present in a range of clinical
forms [4]. Lesions are characterized by development of nodules,
which progress to ulcerative lesions, lasting from between 3
months to three years. Epidermal changes reflect the immune
response to the infection, resulting in hyperplasia and
epidermal thickening. Within the dermis the collagen matrix is
disrupted and fibroblasts are eventually recruited during the
healing process [5]. Epidermal disruption results in discharge
and eventually dries to form an encrusted ulcer, with a central
depression and raised border [6]. It is in this latter region where
parasites are present in dermal macrophages. Resolution
usually occurs following the generation of the appropriate Th1
response and the resulting cytokines (IFNγ, TNFα, IL-12) that
confer resistance to infection with leukocyte migration resulting
in necrosis and formation of a healing granuloma [7]. In the
majority of cases of CL there is a single self-limiting lesion.
Over 17 species of Leishmania cause CL (Table 1) [8,9]. Acute
CL, caused by L major, L tropica and L aethiopica in the Old
World and L braziliensis, L panamenis and L mexicana in the
New World are the most common causes of infection.
Complex and rare manifestations of CL include: (i)
mucocutaneous leishmaniasis (MCL) found in > 5% L
braziliensis cases, often several years after the initial lesion;
(ii) diffuse cutaneous leishmaniasis (DCL), a rare
disseminating anergic disease caused by L aethiopica and L
amazonensis; and (iii) 'recidivans' leishmaniasis (LR) a chronic
disease caused by L tropica and L amazonensis. Parasites that
normally cause visceral leishmaniasis (VL) can also cause
CL; some strains of L infantum can give rise to simple
lesions, whereas post-kala-azar dermal leishmaniasis
(PKDL) is caused by L donovani, usually two years after a
visceral cure [10]. Identifying the causative organism of CL
is important as there is significant variation in the drug
sensitivity of Leishmania species [11].
Table 1. Species of Leishmania causing CL as either primary or secondary manifestations.
Leishmania species Primary pathology Secondary pathology
L(viannia) braziliensis (NW) cutaneous 5% mucocutaneous (espundia)
L(v) peruviana (NW) cutaneous (uta)
L(v) panamensis (NW) cutaneous (ulcera de bejuco) 5% mucocutaneous
L(v)guyanenesis (NW) cutaneous ('pian-bois')
L mexicana (NW) cutaneous (chiclero's ear)
L amazonensis (NW) Cutaneous diffuse CL
L venezuelensis Cutaneous
L pifanoi Cutaneous
L garnhami Cutaneous
L tropica (OW) Cutaneous recidivans
L aethiopica (OW) Cutaneous diffuse CL
L major (OW) Cutaneous
L donovani (OW) visceral (kala-azar) PKDL
L infantum (OW) Visceral CL
L chagasi (NW) Visceral CL
NW New World, OW Old World
Over the past decade, co-infection with HIV has become an
increasing problem, particularly in southern Europe. The
HIV virus hastens the spread of Leishmania and can re-
awaken latent infections, while Leishmania accelerates AIDS
onset [12,13]. It was recently estimated that CL occurs in 2 to
3% of HIV-infected patients [14].
Chemotherapy of cutaneous leishmaniasis
CL is a disfiguring disease that normally resolves within 3 to
18 months of initial infection. Treatment aims to cure as well
as prevent the development of more complex manifestations
like MCL and DCL. Generally the New World species tend
to cause more severe and longer infections than the Old
World species [15,16]. Therapeutic response is dependent on
efficiency of host immune response and genetic makeup.
Unfortunately, many published reports on treatment are
based upon small, uncontrolled clinical trials which give
equivocal results with differences dependent upon patient
selection, parasite strain/virulence, drug regimen,
evaluation criteria and site of infection. Moreover,
spontaneous healing in CL causes additional difficulties in
interpreting treatment data without adequate control
(placebo) groups and trial design.
The standard therapy for CL involves daily injections of
pentavalent antimony for 20 days, either as Pentosam
(sodium stibogluconate) or Glucantime (meglumine
antimonate); clinical use and problems are described
elsewhere [17]. Studies in the Old World have show that
intralesional administration gives superior healing rates
compared to intramuscular antimonials [18,19]. Advantages
of this route of administration include, targeting higher drug
concentrations to the site of infection, lower systemic toxicity,
decreased cost and faster healing time. However, local
therapy alone is not appropriate for the New World L
braziliensis species, which can potentially disseminate. The use
of second line drugs, amphotericin B (AmB; Figure 1) and
pentamidine isethionate, and the parenteral formulation of
the aminoglycoside paromomycin (aminosidine; Figure 2)
have also been described elsewhere [20,21].
Figure 1. Structure of amphotericin B.
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Attempts to investigate possible new therapies have focused
on modestly active oral agents, eg, antifungal azoles and
allopurinol, and local therapy, including cryotherapy,
thermotherapy, surgery and electrotherapy [22]. An open-
label phase I/II clinical trial of oral miltefosine (an
alkylphosphocholine; Figure 3) against CL in South America
gave a 94% cure rate when a dose of 133 to 150 mg/day was
used [23]. Mixed results have been achieved with oral
itraconazole and ketoconazole in clinical trials [24-27].
Immunomodulators including BCG, IFNγ and GM-CSF have
been used alone and in combination with antimonials for the
treatment of CL [28], however, recent trials with a synthetic
immunomodulator, imiquimod (Figure 4), offer a more
realistic option.
Figure 2. Structure of paromomycin.
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Figure 3. Structure of miltefosine.
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Figure 4. Structure of imiquimod.
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Topical treatments
Topical formulations offer significant advantages over
systemic therapy, such as, ease of administration, fewer
adverse effects and cost-effectiveness. Local treatment
remains an attractive approach for simple localized forms of
CL that do not pose a risk of developing complications that
require systemic therapy. This paper reviews the current
status of topical treatments and looks at developments over
the past decade since those described in reference [29].
Renewed interest in the topical treatment of CL began with
the studies of El-On et al on the aminoglycoside,
paromomycin (aminosidine, monomycin, neomycin E)
(Figure 1) [30]. They showed that a 15% paromomycin sulfate
(PM) plus 12% methyl benzethonium chloride (MBCl)
ointment effected a complete cure of L major lesions in
BALB/c mice. In the same series of experiments,
paromomycin in combination with other quaternary
ammonium disinfectants or DMSO (a known penetration
enhancer), gave significant levels of activity. Two other
aminoglycosides, kanamycin and gentamycin in the MBCl
formulation also had some activity, but three others,
neomycin, amikacin and tobramycin, were not active. The
success of this approach in demonstrating the potential of
aminoglycosides as topical antileishmanials contrasted with
parallel studies that showed other antileishmanial drugs
(sodium stibogluconate, pentamidine, AmB, emetine,
metronidazole, co-trimoxazole and allopurinol) to have no
significant activity in this model. Rifampin was the only other
drug that demonstrated some activity. It should be noted that
MBCl alone also has antileishmanial activity [31]. These
studies led to a series of small clinical trials of the PM-MBCl
ointment against cutaneous leishmaniasis caused by L major, L
tropica, L aethiopica, L braziliensis and L mexicana. Initial studies
were mostly carried out in Old World CL [32,33••]. In a
randomized, double-blind, crossover study in patients with L
major infection there was a 74% cure rate, versus 27% in the
placebo control group [33••]. A placebo-controlled trial in
Guatemala [34] and uncontrolled trial in Ecuador [35]
reported 85.7% and 85% cure rates, respectively (twice daily
applications for 20 days), one year post-treatment. These
results contrast with the apparent lack of efficacy in the
placebo-controlled trial in Colombia [36]. This ointment is
commercially available and marketed by TEVA
Pharmaceuticals, Jerusalem. However, early studies also
reported severe irritancy and intolerance (burning, pruritis
and vesicle formation), most probably due to the high
concentration of MBCl, a cationic surfactant that is used as a
disinfectant at 0.1 to 0.2%. Concerns over metastasis led to a
trial of 15% paromomycin/5% MBCl with concomitant
systemic antimony, which gave a 90% cure rate [36].
To circumvent the problem of irritation, other formulations
were studied, most of which contained a penetration
enhancing agent. A formulation of 15% aminosidine with
10% urea in white soft paraffin was the most efficacious in
experimental and clinical studies [37,38]. However clinical
trials of this formulation (twice daily applications for 14
days) in Tunisia [39] and Iran [40] were not effective in
accelerating cure. A clinical trial in Honduras similarly
reported lack of efficacy following three-times daily
applications for 4 weeks, where infection was caused by L
chagasi and L mexicana [41]. More recent studies in Iran have
identified differences between treated and untreated groups
following topical application twice a day for 28 days
[Modabber F, unpublished data]. A formulation of 15% PM
with 10% urea in a cetomagrocol/mineral oil/white
petroleum vehicle is produced by Razak Laboratories,
Tehran, Iran.
In an experimental study using L major-infected BALB/c
mice, PM-MBCl ointment plus gentamicin (an
aminoglycoside that when used alone has limited
antileishmanial activity) was significantly more active than
the PM-MBCl ointment alone [42]. Subsequently, a group at
the Walter Reed Army Institute of Research reported the
antileishmanial activity of 15% PM and 0.5% gentamicin
(WR-279396, PM-G) in a vehicle containing ten surfactants
(unnamed, US patent pending). In experimental models the
PM-G ointment gave a 100% cure of L major and L mexicana
lesions on mice following twice-daily treatment for 10 days;
there was no relapse up to 70 days after the completion of
treatment [43•]. The antileishmanial activity proved better
than the PM-MBCl formulation against L panamenis and L
amazonensis and equivalent to the PM-MBCl formulation
against L major and L mexicana. Importantly, the PM-G
formulation also proved less toxic than the PM-MBCL
formulation. However, preliminary results from a clinical
trial involving 45 CL patients in Colombia reported a 65%
cure rate after 20 days of treatment with the PM-G ointment,
in comparison to a 90% cure rate with the PM-MBCl
ointment after 12 month follow-up [44].
AmB is a recommended second line drug for the treatment
of VL, CL and MCL. Lipid formulations of AmB have
reduced toxicity compared to the parent drug formulation,
AmB deoxycholate (Fungizone). Several AmB liposomal
formulations have proved effective for the treatment of VL
[28] with AmBisome approved for use in the treatment of
adult VL [45]. The activities of lipid AmB formulations have
been compared in experimental L major infections in mice
[46] and intravenous AmBisome has been used to treat MCL
in Brazil [47]. When dispersed in an aqueous solution with 5
to 25% ethanol, topical AmB formulations, such as Amphocil
(colloidal dispersion of cholesterol sulfate and AmB) and
Abelcet (phospholipid/AmB complex), had a curative effect
on lesions caused by L major in mice following 21 days
administration [48]. Fungizone (micellar AmB and sodium
deoxycholate) was ineffective. Subsequently, 17 patients in
Israel were treated with Amphocil dispersed in a 5% ethanol
aqueous solution. The AmB-treated lesions healed faster
than placebo-treated ones in all but one case, who had a
deep ulcerated lesion [49]. A patent has been filed for
addition of ethanol to lipid AmB in topical formulations.
Miltefosine (hexadecylphosphocholine), an
alkylphosphocholine originally developed as an oral
antineoplastic agent, is an active antileishmanial in
experimental models [50] and is now in clinical trials for VL
in India [51]. A topical formulation of miltefosine, Miltex,
has been approved for use in 22 countries for the treatment
of cutaneous malignancies [52]. Miltex contains 6%
miltefosine in a vehicle (Kasacade) comprised of 3-
propyloxypropylene glycol, 3-hexylpropylene glycol and 3-
nonylpropylene glycol. There have been two clinical trials
with Miltex for CL, one in Syria involving 16 patients with
nodular CL (applied twice daily) and a second trial in
Colombia involving 19 patients (applied once-daily for 4
weeks). Neither trial demonstrated efficacy against CL
[Bachmann P, personal communication], although the
potential of oral miltefosine against CL has since been
demonstrated [23]. The absence of a significant response of
CL patients to Miltex contrasts with reported experimental
studies using L mexicana- and L major-infected BALB/c,
CBA/J and C57BL/6 mice where the formulation reduced
lesion size and healed established lesions, although relapse
did occur [53].
Other approaches have exploited improved understanding
of the immunology of leishmaniasis. The generation of nitric
oxide (NO) is an important mechanism by which activated
macrophages kill intracellular Leishmania parasites.
Leishmania sensitivity to NO has been exploited in a number
of clinical studies. In a trial in Ecuador in 16 patients with L
braziliensis infections, administration of an S-nitroso-N-
acetylpenicillamine NO-generating cream led to clinical
improvements being reported [54]. In contrast, a study in
Syria using a different NO-generating cream on 40 patients
had poor results [55]. This formulation used potassium
nitrite in aqueous cream to generate NO when acidified with
various agents. More promisingly, the immunomodulator
imiquimod (Figure 2), an imidazoquinazoline, and its analog
resiquimod (3M Pharmaceuticals/Eli Lilly & Co), stimulated
NO synthesis in vitro and killed Leishmania amastigotes in
macrophages. Imiquimod, commercially available as Aldara
in a 5% cream for the topical treatment of genital warts,
proved effective in treating experimental murine CL caused
by L major [56]. In a subsequent study on antimony-resistant
CL cases in Peru, 12 patients were treated with a
combination of topical 5% imiquimod cream + parenteral
Glucantime for 20 days. All patients responded well to this
combination therapy and there was a 90% cure at the 6
month follow-up [57•].
Several studies have focused on drugs interfering with sterol
biosynthesis. One double-blind trial in Saudi Arabia
investigated the clinical efficacy of topical 1% clotrimazole
(Canesten) and 2% miconazole (Daktarin). Both treatment
groups showed improvements, with clotrimazole being
most effective [58]. Another study in mice examined the
topical versus oral delivery of terbinafine and itraconazole
in BALB/c mice infected with L major [59].
Other experimental studies with L amazonensis-infected
BALB/c mice proved the phenothiazine chlorpromazine and
the tricyclic antidepressant amitriptyline, as 10% ointments in
petroleum, to be ineffective [60]. However, the
antimycobacterial drug clofazamine and the naphthoquinone
plumbagin had a suppressive effect on lesion growth [61,62].
Elsewhere, the dinitrolalanine herbicide trifluralin, a compound
with proven in vitro antileishmanial activity, in a 15% topical
formulation had suppressive effects on L major and L mexicana
lesions in BALB/c mice [63]. More promising experimental
studies have been reported with the plant product licochalcone
A (Central Drug Research Institute; Figure 5), which had
activity against L donovani and L major in experimental models
[64]. 150 Synthetic derivatives have since been tested against
Leishmania in vitro. Two of these compounds, PH-81 and PH-
104 (Royal Danish School of Pharmacy), have been further
tested against L major CL in BALB/c mice. The topical
application of an ointment containing these two chalcones (50
mg/ml, twice daily for 10 days) in white petroleum caused a
pronounced suppressive effect on lesion growth, but did not
result in a cure, although suppression continued for several
weeks after completion of dosing [65].
Figure 5. Structure of licochalcone A.
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The skin and its barrier properties
Topical formulations are faced with a number of barriers,
some of which are shown in Figure 6. The skin consists of: (i)
the stratum corneum (SC); (ii) the viable epidermis, which
generates the SC at the germinative layer and also functions
in metabolism and melanin synthesis; (iii) the dermis, which
provides both mechanical and nutritional support to the
epidermis; and (iv) the appendages - hair follicles, sebaceous
glands, eccrine glands and apocrine glands [66].
Figure 6. Considerations in topical delivery.
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Representing the least permeable late stage of
differentiation, the SC is the greatest barrier to percutaneous
absorption. Most molecules permeate the skin via a tortuous
but continuous lipid intercellular route [67]. An important
consideration in CL is the skin condition. For example,
topical formulations may be applied to open lesions that
have lost the SC barrier property or epithelial thickening
may present an additional hindrance to absorption.
Numerous strategies have been devised to enhance topical
absorption and some are listed in Table 2. These either deal
with optimizing properties for absorption or aim to
transiently disrupt SC barrier properties. Physical methods for
enhancing topical absorption include, iontophoresis,
electroporation and ultrasound [68,69], however, these are in
early stages of development and are not suitable for treating
simple CL. Due to the continuity of the lipid pathway,
chemicals altering the lipid structure can have a significant
effect on percutaneous absorption [70]. Known penetration
enhancers have been used in topical formulations for CL, eg,
DMSO, urea, ethanol and polyglycols. However, most studies
fail to discuss the rational approach to developing the
formulation. Attempts to predict permeability are similarly
crucial in selecting likely candidates for topical delivery [71].
Successful development of topical formulations for CL
necessitates both a rational choice of drug and topical delivery
vehicle [72].
Table 2. Enhancing percutaneous absorption.
Strategy Example
Optimizing physicochemical
properties
Prodrugs
Penetration enhancers DMSO, oleic acid, urea
Optimizing formulation
characteristics
Eutectic mixtures, saturated
systems
Physical methods Sonophoresis, electroporation,
iontophoresis
Particulate carriers Transferosomes, liposomes,
cyclodextrans, emulsions
Metabolic skin activity has been reviewed elsewhere [73,74],
highlighting not only the potential for metabolic inactivation,
but also the possibility for prodrug delivery. Prodrugs can be
used to mask functional groups in an attempt to alter
solubility and permeability characteristics. The modified drug
is rendered pharmacologically inactive and penetrates the SC
to undergo cutaneous biotransformation within the viable
tissues. This reverses the modification and essentially releases
the active drug. A number of studies have been carried out on
non-steroidal anti-inflammatory prodrugs [75,76]. Targeted
drug delivery necessitates identifying features unique to the
invading parasite or lesion. One study in L mexicana-infected
mice found stage-specific cysteine proteases within lesions
[77]. Interestingly, some cysteine protease inhibitors have
been active against BALB/c mice infected with L major [78].
Full enzymatic analysis of Leishmania-infected skin could
identify specific enzymes, which could allow targeting of
prodrugs to infected lesions.
Conclusions
CL is an increasingly prevalent disease causing ulcerative
lesions that are often disfiguring and can leave permanent
scars for which drug therapy is largely inadequate. Topical
treatment offers few adverse effects, better compliance,
reduced costs and is feasible for a rural setting. Currently,
only two marketed topical formulations of an
antileishmanial drug, paromomycin, are available. Studies
are underway to investigate the topical potential of other
candidate antileishmanial drugs. Often these drugs have
undesirable physicochemical properties so novel strategies
are required to enhance absorption. Total flux depends on
drug physicochemical properties combined with the
influence of the delivery vehicle on penetration profiles.
Future development of topical drugs must employ rational
drug design to take account of physicochemical properties
and their effect on percutaneous absorption and retention or
drug release at the sites of infection in the dermis.
Therapeutic efficacy depends on both adequate permeation
and pharmacological potency.
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